Keyvisual giving


Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

ITM Radiotheranostics Satellite Symposium.

Prof M Caplin, Prof P Ruszniewski, Dr G Nicolas and Dr S Glasberg discussed about “Towards Optimizing the Application of Radiotheranostics in the Management of NET Patients” at ENETS 2019

Watch the Video >>

Conclusion of an exclusive licensing and development agreement for Solucin® Targeted Radionuclide Therapy (TRT) in South Korea.

Read more

ITM announced today the appointment of Michael Lee-Chin to its supervisory board, starting May 23, 2019.

Read more

ITM announced today the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added (n.c.a.) Lutetium-177…

Read more

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>